Postherpetic Neuralgia (PHN) Global Market Report 2026
상품코드:1957677
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
대상포진 후 신경통(PHN) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 7억 7,000만 달러에서 2026년에는 8억 2,000만 달러에 이르고, CAGR 6.8%로 성장할 전망입니다. 지난 수년간의 성장에는 대상포진 감염률 증가, 신경병증성 통증에 대한 제한된 치료 옵션, 오피오이드 진통제 의존도, 고령 인구 증가, 병원 내 통증 관리 서비스의 점진적 확대 등이 주요 요인으로 꼽힙니다.
대상포진 후 신경통(PHN) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 10억 6,000만 달러에 이르고, CAGR은 6.5%를 나타낼 전망입니다. 예측 기간 동안 성장 요인으로는 표적 신경병증성 통증 치료제 개발, 생물학적 제제 및 브랜드 의약품의 채택 확대, 온라인 약국 유통 채널의 성장, 환자 중심의 통증 관리에 대한 관심 증가, 외래 및 통원 치료 시설의 확대 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 고령화에 따른 대상포진 유병률 증가, 비오피오이드 계열 통증 관리 요법의 도입 확대, 경피 및 외용 진통 솔루션 사용 증가, 장기 만성 통증 관리에 대한 수요 증가, PHN(대상포진 후 신경통)에 대한 인식 개선 및 조기 진단의 진전 등을 꼽을 수 있습니다.
향후 몇 년 동안 만성 통증 질환의 유병률 증가가 대상포진 후 신경통(PHN) 시장의 성장을 견인할 것으로 예측됩니다. 만성통증은 3개월 이상 지속되거나 재발하는 통증을 말하며, 질병이나 외상의 정상적인 치유 기간을 넘어 지속되어 개인의 일상생활과 삶의 질에 악영향을 미치는 경우가 많습니다. 만성 통증 질환 증가는 고령화 사회의 영향이 크고, 노인일수록 관절염이나 신경장애와 같은 퇴행성 질환에 걸리기 쉬워 장기적인 통증을 유발하기 때문입니다. 대상포진 후 신경통은 신경 관련 통증 메커니즘을 조사하고 장기적인 치료 접근법을 평가하는데 있어 명확한 모델을 제공하기 때문에 만성 통증 연구에서 중요한 역할을 하고 있습니다. 예를 들어, 영국 정부 기관인 건강 개선 및 격차 대책국이 2024년 1월에 발표한 보고서에 따르면, 2023년 16세 이상의 약 18.4%가 장기 근골격계(MSK) 질환을 앓고 있는 것으로 보고되었으며, 이는 2022년 17.6%에서 증가한 수치입니다. 따라서 만성 통증 질환의 유병률 증가는 대상포진 후 신경통(PHN) 시장의 성장을 가속하고 있습니다.
대상포진 후 신경통(PHN) 시장에서 사업을 영위하는 주요 기업들은 제품 포트폴리오 확대, 경쟁력 강화, 그리고 보다 효과적이고 내약성이 좋은 치료법에 대한 미충족 수요를 충족시키기 위해 규제 당국의 승인을 획득하는 데 주력하고 있습니다. 규제 당국의 승인은 정부 보건 당국이 특정 의료 적응증에 대한 의약품 및 치료법의 판매 및 사용을 허가하는 공식적인 승인입니다. 예를 들어, 2023년 2월 인도에 본사를 둔 제약회사 자이더스 생명과학는 대상포진 후 신경통(PHN) 치료를 위한 1일 1회 복용 제네릭 가바펜틴 정제(300mg 및 600mg)의 제조 및 판매에 대해 미국 식품의약국(FDA)으로부터 최종 승인을 받았습니다. 으로부터 최종 승인을 받았습니다. 가바펜틴 정은 수두-대상포진 바이러스의 재활성화에 따른 신경 손상으로 인한 신경병증성 통증의 일종인 PHN의 관리에 사용됩니다. PHN의 치료는 일반적으로 첫날 300mg으로 시작하여 2일째 600mg(300mg 1일 2회), 3일째 900mg(300mg 1일 3회)으로 증량하고, 환자의 반응에 따라 최대 1800mg(600mg 1일 3회)까지 점진적으로 증량합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Postherpetic neuralgia (PHN) is a long-term nerve pain disorder that develops as a complication after an episode of herpes zoster (shingles). It is marked by ongoing, often intense pain in the area where the shingles rash previously occurred, persisting for months or even years after the rash has resolved. Postherpetic neuralgia (PHN) arises from nerve damage caused by reactivation of the varicella-zoster virus and represents the most common complication of shingles, particularly among older adults.
The main types of postherpetic neuralgia (PHN) treatments include patches, drugs, and opioids. Patches are transdermal drug delivery systems applied directly to the skin to allow controlled release of medication into the bloodstream. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by end users such as hospitals, clinics, ambulatory surgical centers, and other healthcare settings.
Tariffs have affected the postherpetic neuralgia market by increasing costs for imported pharmaceutical raw materials and finished drug formulations, impacting pricing and supply consistency. Drug and patch segments are most affected, particularly in regions such as Asia-Pacific and Latin America that rely heavily on cross-border pharmaceutical trade. These tariffs have led to higher treatment costs and slower penetration in cost-sensitive markets. However, they have also encouraged local drug manufacturing, generic drug production, and regional supply chain strengthening to improve market resilience.
The postherpetic neuralgia (phn) market research report is one of a series of new reports from The Business Research Company that provides postherpetic neuralgia (phn) market statistics, including postherpetic neuralgia (phn) industry global market size, regional shares, competitors with a postherpetic neuralgia (phn) market share, detailed postherpetic neuralgia (phn) market segments, market trends and opportunities, and any further data you may need to thrive in the postherpetic neuralgia (phn) industry. This postherpetic neuralgia (phn) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The postherpetic neuralgia (phn) market size has grown strongly in recent years. It will grow from $0.77 billion in 2025 to $0.82 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to increasing incidence of herpes zoster infections, limited treatment options for neuropathic pain, reliance on opioid-based pain management, growing elderly population, gradual expansion of hospital pain management services.
The postherpetic neuralgia (phn) market size is expected to see strong growth in the next few years. It will grow to $1.06 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to development of targeted neuropathic pain therapies, rising adoption of biologic and branded drugs, growth of online pharmacy distribution channels, increasing focus on patient-centric pain management, expansion of outpatient and ambulatory care facilities. Major trends in the forecast period include rising prevalence of shingles in aging population, increasing adoption of non-opioid pain management therapies, growing use of transdermal and topical pain relief solutions, higher demand for long-term chronic pain management, improved awareness and early diagnosis of phn.
The rising prevalence of chronic pain conditions is anticipated to drive the growth of the postherpetic neuralgia (PHN) market in the coming years. Chronic pain is defined as persistent or recurring pain that lasts for more than three months, often extending beyond the normal healing period of an illness or injury and negatively impacting an individual's daily activities and quality of life. The increasing occurrence of chronic pain conditions is largely attributed to an aging population, as older adults are more susceptible to degenerative disorders such as arthritis and neuropathy that result in long-term pain. Postherpetic neuralgia plays an important role in chronic pain research by offering a well-defined model for studying nerve-related pain mechanisms and assessing long-term therapeutic approaches. For instance, in January 2024, according to a report published by the Office for Health Improvement and Disparities, a UK-based government department, approximately 18.4% of individuals aged 16 years and above reported having a long-term musculoskeletal (MSK) condition in 2023, an increase from 17.6% in 2022. Therefore, the growing prevalence of chronic pain conditions is fueling the growth of the postherpetic neuralgia (PHN) market.
Major companies operating in the postherpetic neuralgia (PHN) market are emphasizing the pursuit of regulatory approvals to broaden their product portfolios, strengthen competitive positioning, and address the substantial unmet need for more effective and better-tolerated treatments. Regulatory approvals are formal authorizations issued by government health authorities that permit a drug or therapy to be marketed and used for a specific medical indication. For example, in February 2023, Zydus Lifesciences Ltd., an India-based pharmaceutical company, received final approval from the United States Food and Drug Administration to manufacture and market once-daily generic gabapentin tablets in 300 mg and 600 mg strengths for the treatment of postherpetic neuralgia (PHN). Gabapentin tablets are used to manage PHN, a form of neuropathic pain caused by nerve damage following reactivation of the varicella-zoster virus. For PHN management, dosing typically begins at 300 mg on the first day, increases to 600 mg (300 mg twice daily) on the second day, and 900 mg (300 mg three times daily) on the third day, with gradual titration up to a maximum daily dose of 1800 mg (600 mg three times daily) based on patient response.
In September 2023, Adalvo Limited, a Malta-based pharmaceutical company primarily focused on providing services to other companies, partnered with Lotus Pharmaceutical Co. Ltd. to introduce gabapentin extended-release (ER) tablets in South Korea. This partnership is intended to improve patient access to effective and innovative therapies by launching gabapentin ER in the South Korean market, reinforcing their presence in the neurology segment, and expanding their portfolios with high-value pharmaceutical offerings. Lotus Pharmaceutical Co., Ltd. is a Taiwan-based pharmaceutical company that manufactures treatments for postherpetic neuralgia (PHN).
Major companies operating in the postherpetic neuralgia (phn) market are Pfizer Inc., Merck & Co. Inc., Novartis AG, GlaxoSmithKline plc, Teva Pharmaceutical Industries Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Mylan N.V., Mallinckrodt plc, Merz Therapeutics GmbH, Acorda Therapeutics Inc., Scilex Holding Company, Elorac Inc., Oxford Cannabinoid Technologies Holdings plc, Teikoku Pharma USA Inc., Haisco Pharmaceutical Group Co. Ltd., Eli Lilly and Company, Johnson & Johnson, AbbVie Inc., AstraZeneca plc, Sanofi S.A., Grunenthal GmbH, Endo International plc, Purdue Pharma L.P., Hikma Pharmaceuticals plc, Cipla Limited, Lupin Limited, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd.
North America was the largest region in the postherpetic neuralgia (PHN) market in 2025. The regions covered in the postherpetic neuralgia (phn) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the postherpetic neuralgia (phn) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The postherpetic neuralgia (PHN) market includes revenues earned by entities by providing services such as medical consultation, pain management services, topical treatment application, physical therapy and nerve block or injections. The market value includes the value of related goods sold by the service provider or included within the service offering. The postherpetic neuralgia (PHN) market consists of sales of anticonvulsants, amitriptyline, tramadol, oxycodone, and nortriptyline. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Postherpetic Neuralgia (PHN) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses postherpetic neuralgia (phn) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for postherpetic neuralgia (phn) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The postherpetic neuralgia (phn) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Type: Patches; Drugs; Opioids
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End Users: Hospitals; Clinics; Other End Users
Subsegments:
1) By Patches: Transdermal Drug Delivery Patches; Analgesic Patches
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
4.1.5 Immersive Technologies (Ar/Vr/Xr) & Digital Experiences
4.2. Major Trends
4.2.1 Rising Prevalence Of Shingles In Aging Population
4.2.2 Increasing Adoption Of Non-Opioid Pain Management Therapies
4.2.3 Growing Use Of Transdermal And Topical Pain Relief Solutions
4.2.4 Higher Demand For Long-Term Chronic Pain Management
4.2.5 Improved Awareness And Early Diagnosis Of Phn
5. Postherpetic Neuralgia (PHN) Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Clinics
5.3 Ambulatory Surgical Centers
5.4 Pain Management Centers
5.5 Home Healthcare Providers
6. Postherpetic Neuralgia (PHN) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Postherpetic Neuralgia (PHN) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Postherpetic Neuralgia (PHN) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Postherpetic Neuralgia (PHN) Market Size, Comparisons And Growth Rate Analysis
7.3. Global Postherpetic Neuralgia (PHN) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Postherpetic Neuralgia (PHN) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Postherpetic Neuralgia (PHN) Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Postherpetic Neuralgia (PHN) Market
12.1. China Postherpetic Neuralgia (PHN) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Postherpetic Neuralgia (PHN) Market
13.1. India Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Postherpetic Neuralgia (PHN) Market
14.1. Japan Postherpetic Neuralgia (PHN) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Postherpetic Neuralgia (PHN) Market
15.1. Australia Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Postherpetic Neuralgia (PHN) Market
16.1. Indonesia Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Postherpetic Neuralgia (PHN) Market
17.1. South Korea Postherpetic Neuralgia (PHN) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Postherpetic Neuralgia (PHN) Market
19.1. South East Asia Postherpetic Neuralgia (PHN) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Postherpetic Neuralgia (PHN) Market
20.1. Western Europe Postherpetic Neuralgia (PHN) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Postherpetic Neuralgia (PHN) Market
21.1. UK Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Postherpetic Neuralgia (PHN) Market
22.1. Germany Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Postherpetic Neuralgia (PHN) Market
23.1. France Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Postherpetic Neuralgia (PHN) Market
24.1. Italy Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Postherpetic Neuralgia (PHN) Market
25.1. Spain Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Postherpetic Neuralgia (PHN) Market
26.1. Eastern Europe Postherpetic Neuralgia (PHN) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Postherpetic Neuralgia (PHN) Market
27.1. Russia Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Postherpetic Neuralgia (PHN) Market
28.1. North America Postherpetic Neuralgia (PHN) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Postherpetic Neuralgia (PHN) Market
29.1. USA Postherpetic Neuralgia (PHN) Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Postherpetic Neuralgia (PHN) Market
31.1. South America Postherpetic Neuralgia (PHN) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Postherpetic Neuralgia (PHN) Market
32.1. Brazil Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Postherpetic Neuralgia (PHN) Market
33.1. Middle East Postherpetic Neuralgia (PHN) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Postherpetic Neuralgia (PHN) Market
34.1. Africa Postherpetic Neuralgia (PHN) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Postherpetic Neuralgia (PHN) Market, Segmentation By Type, Segmentation By Distribution Channel, Segmentation By End Users, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Postherpetic Neuralgia (PHN) Market Regulatory and Investment Landscape
36. Postherpetic Neuralgia (PHN) Market Competitive Landscape And Company Profiles
